Triclosan, a topical dermatologic agent. In vitro- and in vivo studies on the effectiveness of a new preparation in the New German Formulary;Triclosan, ein dermatologisches lokaltherapeutikum: In-vitro- und In-vivo-untersuchungen zur antibakteriellen Wirksamkeit einer Neuen Arzneibuchrezeptur

Hautarzt

Volumn 53, Issue 11, 2002, Pages 724-729

  Gloor, M ^a   Becker, A ^b   Wasik, B ^a   Kniehl, E ^b  

^a Stadt Karlsruhe   (Germany)

^b Klinikum Karlsruhe GGmbH   (Germany)

Author keywords

Antiseptics; Atopic dermatitis. Venous leg ulcer; Staphylococcus aureus; Triclosan

Indexed keywords

ANTIINFECTIVE AGENT; CHLORHEXIDINE; TRICLOSAN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTISEPSIS; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; BETA HEMOLYTIC STREPTOCOCCUS; CANDIDA; CONTROLLED STUDY; CREAM; DRUG FORMULATION; ECZEMA; ENTEROCOCCUS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN EXPERIMENT; HYDROPHOBICITY; KLEBSIELLA; LEG ULCER; MALE; NONHUMAN; NORMAL HUMAN; PROTEUS; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, TOPICAL; ADULT; BACTERIA; COLONY COUNT, MICROBIAL; DERMATITIS, ATOPIC; DRUG EVALUATION; FEMALE; GERMANY; HUMANS; LEG DERMATOSES; LEG ULCER; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SKIN DISEASES, BACTERIAL; TRICLOSAN; VEHICLES;

EID: 0036940063     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-002-0416-y     Document Type: Article

References (23)

1. Abeck D, Ruzicka T (1991) Bacteria and atopic eczema: merely association or etiologic factor? In: Ruzicka T, Ring J, Przybilla B (eds) Handbook of atopic eczema. Springer, Berlin Heidelberg New York Tokyo, pp 212-220
2. Ryan TJ,Burnand K (1998) Diseases of the veins and arteries: leg ulcers. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds) Textbook of Dermatology, 6th edn. Blackwell Scientific Publications, London Edinburgh Boston Melbourne Paris Berlin Wien, pp 1963-2013
3. Vischer WA, Regös J, (1974) Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. Zentbl Bakteriol Mikrobiol Hyg 1 Abt Orig. A 226:376-389
4. Bruchhausen F von, Dannhardt D, Ebel S, Frahm AW, Hackethal E, Holzgrabe U (1999) Hagers Handbuch der Pharmazeutischen Praxis, Bd 9, 5. Aufl. Springer, Berlin Heidelberg New York, S 1046-1047
5. Wallhäußer KH (1995) Praxis derSterilisation, Desinfektion, Konservierung, 5. Aufl. G. Ghieme, Stuttgart New York, S 1046-1047
6. Bhargava HN,Leonhard PA (1996) Triclosan: application and saftey. Am J Infect Contr 24:209-218
7. Leyden JJ, Stewart R, Kligman AM (1979) Updated in vivo methods for evaluating topical antimicrobial agents on human skin. J Invest Dermatol 72:165-170
8. Williamson O, Kligman AM (1965) A new method for quantitative investigation of cutaneous bacteria. J Invest Dermatol 45:498-503
9. Cole GW, Silverberg NL (1986) The adherence of staphylococcus aureus to human corneocytes, Arch Dermatol 122:166-169
10. Mc Fadden JP, Noble WC, Camp RDR (1993) Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol 128:631-632
11. Strom K, Abeck D (1999) Atopisches Ekzem. In: Traupe H, Hamm H (Hrsg) Pädiatrische Dermatologie. Springer, Berlin Heidelberg New York Tokyo, S 420
12. Gloor M,Gehring W (2001) Increase and protective function of horny layer by glycerol and a w/o emulsion: are these effects maitained during long-term use? Contact Dermat 44:46
13. McMurry LM, Oethinger M, Levy SB (1998) Triclosan targets lipid synthesis. Nature 394:531-532
14. Heath RJ, Rock CO (2000) A triclosan-resistant bacterial enzyme. Nature 406:145-146
15. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer RR, Schweizer HP (2001) cross-resistance between triclosan and antibiotics in pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 45:428-432
16. Fluhr JW, Gloor M (1997) Alternativvorschläge für die obsoleten Rezepturen Solutio Castellani und Fabry Spiritus - In vivo Wirksamkeitsnachweis und toxikologische Bewertung. Akt Dermatol 23:252-256
17. Gloor M, Reichling J,Wasik B, Holzgang HE (2002) Antiseptic effect of a topical dermatological that contains hamamelis destillate and urea. Forsch Komplementarmed Klass Naturheilkd 9:153-159
18. Gehring W, Forssman T, Jost G, Gloor M (1996) Die keimreduzierende Wirkung von Erythromycin und Triclosan bei der atopischen Dermatitis. Akt Dermatol 22:28-31
19. Marzulli FN, Bruch M (1981) Antimicrobial soaps: benefits versus risks. In: Maibach H, Aly R (eds) Skin microbiology-relevance to clinical infection. Springer, Berlin Heidelberg New York, pp 125-134
20. Veronisi S, de Padova MP, Vanni D, Melino M (1986) Contact dermatitis to triclosan Contact Dermat 15:257
21. Moss T, Howes D, Williams FW (2000) Percutaneous penetration and dermal metabolism of triclosan(2,4,4′-trichloro-2′-hydroxydiphenyl ether). Food Chem. Toxicol 38:361-370
22. Kanetoshi A, Katsura E, Ogawa T, Kaneshima H, Miura T (1992) Acute toxicity, percutaneous absorption and effects on hepatic mixed function oxidase activities of 2,4,4′-trichloro-2′hydroxydiphenylether (Irgasan DP 300) and its chlorinated derivates. Arch Environ Contam Toxicol 23:91-98
23. Hanioka N, Omae E, Nishimura T, Jinno H, Onodera S, Yoda R, Ando M (1996) Interaction of 2,4,4′-trichloro-2′-hydroxydiphenyl ether with microsomal cytochrome P 450-dependent monocytogenases in rat liver. Chemosphere 3:265-276